REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Net Product Revenues by Product (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from External Customer [Line Items]
Revenue	$ 505,344	$ 408,742	$ 1,558,501	$ 1,396,465
Product
Revenue from External Customer [Line Items]
Revenue	493,348	393,840	1,516,533	1,348,279
VIMIZIM | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	155,470	136,744	511,735	466,697
NAGLAZYME | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	99,506	71,172	343,320	297,321
PALYNZIQ | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	66,206	60,729	182,734	173,702
KUVAN | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	57,038	67,687	173,977	217,257
VOXZOGO | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	48,289	144	102,321	144
BRINEURA | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	37,793	32,984	111,691	90,641
Total net product revenues marketed by the Company | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	464,302	369,460	1,425,778	1,245,762
ALDURAZYME net product revenues marketed by Sanofi | Marketed by Sanofi
Revenue from External Customer [Line Items]
Revenue	29,046	24,380	90,755	102,517
Royalty and other revenues
Revenue from External Customer [Line Items]
Revenue	$ 11,996	$ 14,902	$ 41,968	$ 48,186